Statistical process control for IMRT dosimetric verification

被引:67
作者
Breen, Stephen L. [1 ,2 ]
Moseley, Douglas J. [1 ,2 ]
Zhang, Beibei [1 ]
Sharpe, Michael B. [1 ,2 ]
机构
[1] Princess Margaret Hosp, Dept Radiat Phys, Toronto, ON M5G 2M9, Canada
[2] Univ Toronto, Dept Radiat Oncol, Fac Med, Toronto, ON M5S 3E2, Canada
关键词
D O I
10.1118/1.2975144
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Patient-specific measurements are typically used to validate the dosimetry of intensity-modulated radiotherapy (IMRT). To evaluate the dosimetric performance over time of our IMRT process, we have used statistical process control (SPC) concepts to analyze the measurements from 330 head and neck (H&N) treatment plans. The objectives of the present work are to: (i) Review the dosimetric measurements of a large series of consecutive head and neck treatment plans to better understand appropriate dosimetric tolerances; (ii) analyze the results with SPC to develop action levels for measured discrepancies; (iii) develop estimates for the number of measurements that are required to describe IMRT dosimetry in the clinical setting; and (iv) evaluate with SPC a new beam model in our planning system. H&N IMRT cases were planned with the PINNACLE3 treatment planning system versions 6.2b or 7.6c (Philips Medical Systems, Madison, WI) and treated on Varian (Palo Alto, CA) or Elekta (Crawley, UK) linacs. As part of regular quality assurance, plans were recalculated on a 20-cm-diam cylindrical phantom, and ion chamber measurements were made in high-dose volumes (the PTV with highest dose) and in low-dose volumes (spinal cord organ-at-risk, OR). Differences between the planned and measured doses were recorded as a percentage of the planned dose. Differences were stable over time. Measurements with PINNACLE(3) 6.2b and Varian linacs showed a mean difference of 0.6% for PTVs (n=149, range, -4.3% to 6.6%), while OR measurements showed a larger systematic discrepancy (mean 4.5%, range -4.5% to 16.3%) that was due to well-known limitations of the MLC model in the earlier version of the planning system. Measurements with PINNACLE(3) 7.6c and Varian linacs demonstrated a mean difference of 0.2% for PTVs (n=160, range, -3.0%, to 5.0%) and -1.0% for ORs (range -5.8% to 4.4%). The capability index (ratio of specification range to range of the data) was 1.3 for the PTV data, indicating that almost all measurements were within +/- 5%. We have used SPC tools to evaluate a new beam model in our planning system to produce a systematic difference of -0.6% for PTVs and 0.4% for ORs, although the number of measurements is smaller (n=25). Analysis of this large series of H&N IMRT measurements demonstrated that our IMRT dosimetry was stable over time and within accepted tolerances. These data provide useful information for assessing alterations to beam models in the planning system. IMRT is enhanced by the addition of statistical process control to traditional quality control procedures. (C) 2008 American Association of Physicists in Medicine.
引用
收藏
页码:4417 / 4425
页数:9
相关论文
共 18 条
  • [1] Dosimetric considerations for validation of a sequential IMRT process with a commercial treatment planning system
    Cadman, P
    Bassalow, R
    Sidhu, NPS
    Ibbott, G
    Nelson, A
    [J]. PHYSICS IN MEDICINE AND BIOLOGY, 2002, 47 (16) : 3001 - 3010
  • [2] Validation of physics improvements for IMRT with a commercial treatment-planning system
    Cadman, Patrick
    McNutt, Todd
    Bzdusek, Karl
    [J]. JOURNAL OF APPLIED CLINICAL MEDICAL PHYSICS, 2005, 6 (02): : 74 - 86
  • [3] Patient-specific point dose measurement for IMRT monitor unit verification
    Dong, L
    Antolak, J
    Salehpour, M
    Forster, K
    O'Neill, L
    Kendall, R
    Rosen, I
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 56 (03): : 867 - 877
  • [4] Guidance document on delivery, treatment planning, and clinical implementation of IMRT: Report of the IMRT subcommittee of the AAPM radiation therapy committee
    Ezzell, GA
    Galvin, JM
    Low, D
    Palta, JR
    Rosen, I
    Sharpe, MB
    Xia, P
    Xiao, Y
    Xing, L
    Yu, CX
    [J]. MEDICAL PHYSICS, 2003, 30 (08) : 2089 - 2115
  • [5] American Association of Physicists in Medicine radiation therapy committee task group 53: Quality assurance for clinical radiotherapy treatment planning
    Fraass, B
    Doppke, K
    Hunt, M
    Kutcher, G
    Starkschall, G
    Stern, R
    Van Dyke, J
    [J]. MEDICAL PHYSICS, 1998, 25 (10) : 1773 - 1829
  • [6] Implementing IMRT in clinical practice: A joint document of the American Society for Therapeutic Radiology and Oncology and the American Association of Physicists in Medicine
    Galvin, JM
    Ezzell, G
    Eisbrauch, A
    Yu, C
    Butler, B
    Xiao, Y
    Rosen, I
    Rosenman, J
    Sharpe, M
    Xing, L
    Xia, P
    Lomax, T
    Low, DA
    Palta, J
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 58 (05): : 1616 - 1634
  • [7] Int. Organ. Stand, 1994, 9000 ISO
  • [8] COMPREHENSIVE QA FOR RADIATION ONCOLOGY - REPORT OF AAPM RADIATION-THERAPY COMMITTEE TASK-GROUP-40
    KUTCHER, GJ
    COIA, L
    GILLIN, M
    HANSON, WF
    LEIBEL, S
    MORTON, RJ
    PALTA, JR
    PURDY, JA
    REINSTEIN, LE
    SVENSSON, GK
    WELLER, M
    WINGFIELD, L
    [J]. MEDICAL PHYSICS, 1994, 21 (04) : 581 - 618
  • [9] LIGHTER DE, 2000, PRINCIPLES METHODS Q
  • [10] LIN HC, 2005, QUAL ENG, V17, P371